arrow
S

Sattva S. Neelapu

Department of Lymphoma and Myeloma
H指数:83
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

为复发/难治性B细胞恶性疾病启用talicabtagene autoleucel的获取途径;关于其配送、有效性和安全性的多中心真实世界证据

2026-07-160
OA
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

SMART START试验的长期临床结果:利妥昔单抗、来那度胺和伊布替尼在 newly diagnosed large B-cell lymphoma 患者中的应用

2026-07-020
OAAI
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies

关于未来早期CAR T疗法研究中定义嵌合抗原受体T细胞(CAR T)剂量限制性毒性(DLTs)的建议

2025-11-070
PRE
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>

勘误:《免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征》\[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9\]

2025-10-300
OAAI
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

一线阿卡巴鲁替尼、来那度胺和利妥昔单抗治疗高肿瘤负荷的晚期滤泡性淋巴瘤:II期试验

2025-08-070
OAAI
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma

一项奥滨尤妥珠单抗联合来那度胺治疗既往未治的高肿瘤负荷滤泡性淋巴瘤的II期研究

2025-06-170
OAAI
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma

与检查点抑制剂相关的肺炎在复发或难治性淋巴瘤中的发生率和危险因素

2025-05-160
PRE
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

纳武利尤单抗联合罗特利珠单抗治疗复发或进展性B细胞恶性肿瘤的RELATIVITY-022研究

2025-03-050
OA
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy
2025-03-010
PRE
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
2025-01-310
OAAI
Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

CAR T细胞疗法后免疫效应细胞相关神经毒性综合征(ICANS)中成像活化的先天免疫髓系细胞

BLOOD
IF23.1
2024-11-051
PRE
Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

个性化新抗原肽疫苗联合或不联合来那度胺用于中危或高危冒烟型多发性骨髓瘤(SMM)患者,以预防进展为多发性骨髓瘤(MM)

BLOOD
IF23.1
2024-11-050
PRE
Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

放射治疗与接受CAR T细胞疗法的大B细胞淋巴瘤患者的单核细胞激活

BLOOD
IF23.1
2024-11-050
PRE
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Treated with Ciloleucel

炎症、肿瘤和产品属性对接受Ciloleucel治疗的复发/难治性滤泡性淋巴瘤患者临床结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs
2024-09-110
OAAI